Literature DB >> 7330581

Quantitation and localisation of aluminum in human cancellous bone in renal osteodystrophy.

B F Boyce, H Y Eider, S G Fell, W A Nicholson, G D Smith, D W Dempster, C C Gray, I T Boyle.   

Abstract

There is increasing evidence that aluminium toxicity may be responsible for a type of vitamin D-resistant osteomalacia and an unusually severe form of dementia ("dialysis dementia") occurring in some patients with chronic renal failure on regular haemodialysis. High concentrations of Al have been found in blood, bone and brain tissue from these patients. The A1 comes either from the water used during dialysis (added in some public water supplies during purification to precipitate contaminants) or from aluminium salts taken orally to bind phosphates and so restrict their dietary adsorption. Recent X-ray microanalytical studies have demonstrated Al in lysosomes of cerebral cells and at the calcification front in bone of patients dying of dialysis dementia but its concentration at this site in bone has not been measured using this technique. We have examined transiliac bone biopsies from 3 patients with dialysis dementia and 6 non-demented patients on regular haemodialysis, Atomic absorption spectrometry (AAS) reveals high Al content in bone from the 3 demented and 2 of the non-demented patients. All had vitamin D-resistant osteomalacia. Using X-ray microanalysis Al was located in the bone of these five patients only. The Al had a highly focal distribution and was measured at up to 40 times higher concentration than by AAS but only in mineralisation nuclei of the calcification front or less than 2 micrometer into the mineralized bone. The study was done retrospectively on biopsies fixed in 10% buffered formalin, which almost certainly eluted some of the Al. In life, Al levels may have been higher than those we have detected.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7330581

Source DB:  PubMed          Journal:  Scan Electron Microsc        ISSN: 0586-5581


  7 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

2.  Analytical procedures for diagnosis of trace element disorders.

Authors:  G S Fell
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

3.  Aluminium-induced dialysis eosteomalacia.

Authors:  H A Ellis; W H Mawhinney
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

4.  Effects of aluminum(III), chromium(III), and iron(III) on the rate of dissolution of calcium hydroxyapatite crystals in the absence and presence of the chelating agent desferrioxamine.

Authors:  M R Christoffersen; H C Thyregod; J Christoffersen
Journal:  Calcif Tissue Int       Date:  1987-07       Impact factor: 4.333

5.  The effect of aluminum on the rate of dissolution of calcium hydroxyapatite--a contribution to the understanding of aluminum-induced bone diseases.

Authors:  M R Christoffersen; J Christoffersen
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

6.  Histological and electron microprobe studies of mineralisation in aluminium-related osteomalacia.

Authors:  B F Boyce; J Byars; S McWilliams; M Z Mocan; H Y Elder; I T Boyle; B J Junor
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

Review 7.  Metabolism and possible health effects of aluminum.

Authors:  P O Ganrot
Journal:  Environ Health Perspect       Date:  1986-03       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.